Authors’ Reply to Ganijee et al.: “Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults”

Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat

“…No dose-dependent trend on hemodynamic parameters across the different sildenafil doses was evident [ 45 ]. However, concomitant use of vericiguat and PDE5 inhibitors has not been studied in patients with HFrEF [ 10 ], and is therefore not recommended because of the potential increased risk for symptomatic hypotension [ 7 , 8 , 46 ].…”